Dual AAV vector strategy for Usher syndrome type 1B shows preclinical safety data

A bioRxiv preprint reports preclinical development and safety evaluation of laterally spreading dual AAV vectors designed to deliver the large MYO7A gene in a model of the most severe form of Usher syndrome.

Published · AI-drafted summary based on 1 public source
Illustration for rare disease story
Illustrative image — not from the source article.
Share

A preprint deposited on bioRxiv describes the preclinical development of a dual adeno-associated virus (AAV) gene therapy strategy targeting Usher syndrome type 1B (USH1B), the most common and most severe subtype of Usher syndrome. USH1B is caused by mutations in MYO7A and presents at birth with profound deafness and vestibular dysfunction, with progressive retinitis pigmentosa developing over time. No approved treatment currently exists.

The central technical challenge is that the MYO7A coding sequence exceeds the packaging capacity of a single AAV vector, which is the most widely used delivery platform for retinal gene therapies. The authors report that they developed dual AAV hybrid and overlap platforms designed to reconstitute full-length MYO7A expression in photoreceptors and retinal pigment epithelium. The preprint details safety evaluations in preclinical models, describing what the authors term a 'laterally spreading' mechanism intended to widen the transduction footprint beyond the injection site.

The work has not yet been peer-reviewed. For researchers and genetic counsellors with an interest in inherited retinal dystrophies, the study represents a methodological step in addressing the vector-capacity barrier that has long complicated gene therapy development for large-gene conditions. The authors make no clinical claims. This type of research is part of an active field working to translate gene therapy approaches to a group of rare diseases that currently have no approved pharmacological treatment.

Plain-language version

For patients, families, and general readers. Educational only — not medical advice.

Usher syndrome type 1B is a rare inherited condition that causes profound deafness from birth and, over time, leads to progressive loss of vision due to a condition called retinitis pigmentosa. It is caused by faults in a gene called MYO7A. Researchers have published early-stage laboratory results — not yet independently reviewed — describing a new way to try to deliver a working copy of the MYO7A gene into the cells of the retina. The difficulty is that this gene is too large to fit inside the microscopic biological 'package' (called a virus vector) normally used for this kind of gene therapy, so the team developed a two-part system to get around this problem. The work is at a preclinical stage, meaning it has been tested in laboratory models and has not yet been tested in people. There is no approved treatment for Usher syndrome type 1B at this time. This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.

Sources

Read the original reporting — these are the public sources this summary draws from.

  1. Primary sourcePreprint bioRxiv (Cold Spring Harbor Laboratory) · 2026-10-29
    Preclinical Development and Safety of Laterally Spreading Dual AAV.SPR-MYO7A Vectors for the Treatment of Usher Syndrome Type 1B

Tags

usher-syndrome myo7a aav gene-therapy retinitis-pigmentosa inherited-retinal-dystrophy rare-disease preprint
Share

About Genetic Current

Educational summaries of public genetics news

Genetic Current is the news section of Evagene, an academic, research, and educational pedigree-modelling platform. Stories are AI-drafted summaries of items from trusted public sources, written for researchers, clinicians, educators, students, genealogists, and patients with an interest in genetics. Summaries are for educational and research purposes only and are not medical advice.

Join the Evagene Alpha Waiting List